Novel Coronavirus Control Using Alcohol Based Mouthwash &CoVid-19 Facts…..
June 26, 2021 Update:
A few weeks ago, I was going to the doctor and ended up with CoVid-19. The very next day, I developed uncontrollable cough that kept me up the whole night. A CoVid-19 test was performed, and it turned out to be positive. I self quarantined for 2 weeks. Treatment was only antiseptic mouthwash twice a day and Golden Milk. (Recipe can be found here http://reach4dstars.info/2021/06/20/foods-that-heal/ )
I had headaches and slept a lot. It was a mild respiratory infection.
Doctors told me that I would test positive for three months, but not infectious after the recovery.
January 6, 2021 Update:
The U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.Oct 22, 2020 FDA Approves First Treatment for COVID-1
Baricitinib is a janus kinase inhibitor, which blocks the activity of one or more of a specific family of enzymes, interfering with the pathway that leads to inflammation. Baricitinib is a prescription oral tablet medication that is FDA-approved (and sold under the brand name Olumiant) for the treatment of moderately to severely active rheumatoid arthritis. Under today’s EUA, the FDA is authorizing the emergency use of baricitinib, in combination with remdesivir, for the treatment of certain hospitalized patients with suspected or laboratory-confirmed COVID-19.
Remdesivir is an FDA-approved (and sold under the brand name Veklury) intravenous antiviral drug for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Remdesivir also remains authorized for emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg (about 7.7 pounds) to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg.
“The FDA’s emergency authorization of this combination therapy represents an incremental step forward in the treatment of COVID-19 in hospitalized patients, and FDA’s first authorization of a drug that acts on the inflammation pathway,” said Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation and Research. “Despite advances in the management of COVID-19 infection since the onset of the pandemic, we need more therapies to accelerate recovery and additional clinical research will be essential to identifying therapies that slow disease progression and lower mortality in the sicker patients.”
The issuance of an EUA is different than an FDA approval. In determining whether to issue an EUA, the FDA evaluates the totality of available scientific evidence and carefully balances any known or potential risks with any known or potential benefits of the product for use during an emergency. Based on the FDA’s review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that baricitinib, in combination with remdesivir, may be effective in treating COVID-19 for the authorized population. And, when used under the conditions described in the EUA to treat COVID-19, the known and potential benefits of baricitinib outweigh the known and potential risks for the drug. There are no adequate, approved and available alternative treatments to baricitinib, when used in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or ECMO.
The data supporting this EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). This clinical trial evaluated whether baricitinib impacted how long it took for subjects who were also taking remdesivir to recover from COVID-19. The trial followed patients for 29 days and included 1,033 patients with moderate or severe COVID-19; 515 patients received baricitinib plus remdesivir, and 518 patients received placebo plus remdesivir. Recovery was defined as either being discharged from the hospital or being hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care. The median time to recovery from COVID-19 was seven days for baricitinib plus remdesivir and eight days for placebo plus remdesivir. The odds of a patient’s condition progressing to death or being ventilated at day 29 was lower in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. The odds of clinical improvement at day 15 was higher in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. For all of these endpoints, the effects were statistically significant.
Under the EUA, fact sheets that provide important information about using baricitinib in combination with remdesivir in treating COVID-19 as authorized must be made available to health care providers and to patients and caregivers. These fact sheets include dosing instructions, potential side effects and drug interactions. Possible side effects of baricitinib in combination with remdesivir include serious infections, blood clots, changes in certain lab test results and allergic reactions.
The EUA was issued to Eli Lilly and Company.
Many COVID-19 patients in the ICU are developing blood clots, including clots in small vessels, deep vein thromboses in the legs, clots in the lungs, and stroke-causing clots in cerebral arteries. This has been happening even though these patients, in accordance with standard intensive care practice, are put on blood thinner drugs such as heparin to prevent clots as soon as they come to the ICU. This COVID-19-related clotting often does not respond well to standard prevention methods and, in some cases, to standard treatments, even with high doses of blood thinners.
January 3, 2021
Introduction
In February 2020, I was invited to research CoVid-19. The disease was new, a lot of people were getting sick and dying from it. Doctors did not know how to treat it. Doctors were experimenting what they believed was the best way to approach the disease.
I am part of an online patent research community. This community involves researchers worldwide and only the best work gets the prize money. This requires a worldwide online library since we have to make sure the work is original.
In my first research attempt, I did very well and got paid. When I have time, I would do this on the side.
I decided to do the CoVid-19 research. The study was looking for novel ideas to prevent the spread of the virus. I had personal observations with mouthwash and masks and decided to include it in the study. My work got submitted to an international site, so other researchers from other countries can test my observations (hypothesis)
#1. The use of alcohol based mouthwash
I was working with the disabled and elderly as a home health care worker. I had a client with itchy rashes that was not responding to the conventional treatments. We believed it was a fungal infrection. A nurse came by and told me about the use of alcohol based mouthwash with menthol cleared up skin infection quickly. We tried it and it worked in 2–3 days.
I use alcohol based mouthwash before going to work. At one time, I developed a sore throat and utilized the mouthwash and observed the sore throat got relieved and got well within 1–2 days. In a later incident, I did not use mouthwash and I got sicker. When I used it, I observed the healing period got shorter.
With these observations in mind, I decided to add it to my CoVid-19 report, to fulfill the “novel preventative measure” requirement of the study.
The original report included treatments based on the scientific research. I did not include these treatments here. The treatments are for the medical communities.
Summary
The use of alcohol and menthol based mouthwash is a cheap way of preventing CoVid-19, in addition to current protocols of wearing face masks and washing hands frequently. Vaccines were not available when I first wrote this.
My goal is to prevent the spread of CoVid-19. Since vaccines are not readily available, the use of alcohol based mouthwash with menthol might help.
Disclaimer
I cannot guarantee the success of the alcohol based + menthol mouthwash as a preventative to the CoVid-19. Nor can CoVid-19 vaccine manufacturers can guaranteer its success and side effects.
Updates as of December 26, 2020:
Current Vaccine Development Studies
As of December 22, 2020, CDC CoVid tracker, (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days, as of December 22, 2020 there are 17,974,303 cases in the United States, with an additional 183,927 new cases. The average daily cases per 100,000 in past 7 days is 66. Total Deaths is 318,560, with additional 1,725 new deaths.
As of December 25, 2020, California is the first state to hit 2 million cases and area hospitals are out of ICU beds.
Holding funeral services and visitations
Familial and cultural expectations might put pressure on you and others to participate in or hold or schedule funeral services and visitations. During the COVID-19 pandemic, those expectations may need to be relaxed to protect the safety of those who would have participated. People continue to get exposed to COVID-19 at funeral services; the people giving it to others were not feeling sick at the time and did not know they were carrying or spreading COVID-19.Consider the following modifications to funeral services and visitations to help prevent the spread of COVID-19. These modifications are recommended for events held in any setting, including funeral homes, cemetery facilities, places of worship, private homes, and other venues.
Limit the attendees to a small number of immediate family and close friends
- Follow the guidelines from state and local officials and state and local external icon health departments.
- Those who are sick, have a household member or other close contact who is sick. Those who have higher risk of severe illness should weigh the benefits of in-person attendance against risk of exposure to a person with COVID-19, especially if recommendations for wearing masks and social distancing may be difficult to follow for themselves or others
- Consider limiting the number of people from different areas of the country or any areas with significant spread of COVID-19.
- Consider offering other ways for family and friends to participate, such as by phone or online (live or recorded).
Practice social distancing and everyday preventive actions
- Consider holding services and gatherings in a large, well-ventilated area or outdoors, as circumstances and traditions allow.
- Space out seating for attendees who do not live in the same household to at least 6 feet apart between household groups.
- Attendees who do not live in the same household should stay at least 6 feet (2 meters) apart and wear a mask when interacting with people who do not live in their household.
- People who have been living in the same household can comfort each other in typical ways such as hugging, holding hands, and sitting next to each other.
- Attendees should nod, bow, or wave instead of holding or shaking hands, hugging, or kissing anyone who does not live in their household.
- Consider limiting the number of people engaged in activities that produce respiratory droplets, which may contain virus, (e.g., singing or chanting) especially when participants are indoors and in close proximity to each other. If attendees choose to sing or chant, encourage them to wear masks and increase distance between people to greater than 6 feet.
- All attendees should follow everyday preventive actions to protect themselves and others from COVID-19, such as washing your hands often and covering coughs and sneezes.
Consider changing traditional rituals or practices
Discuss with the funeral home director, clergy or officiant, and your family any potential changes that might be necessary to protect all of the participants and attendees. Consider options for modified or new practices that would be acceptable to you and your family and friends, such as:
- Holding a graveside-only service.
- Changing or removing funeral practices that involve close contact or sharing things among members of different households, such as:
- Sharing a car or limousine ride between the church and cemetery.
- Providing food and beverages for attendees after the service.
- Changing religious rituals in consultation with clergy and other religious leaders.
If some traditions, such as certain religious rituals, sharing rides to the gravesite, or having food and beverages, are considered essential to you and your family and friends, consider modifying them.
- Limit sharing of items, such as worship aids, prayer books, and other items shared or passed by clergy and attendees during religious rituals.
- Group household members together inside the vehicle. Avoid having non-household members sharing vehicles to travel between locations during the services; if necessary, increase ventilation by opening windows or using the air conditioner on non-recirculating mode.
- If food is offered at a reception, have individual pre-packaged boxes or bags instead of a potluck, buffet, or family-style meal. Avoid sharing of foods and utensils.
In some cultures, bringing food or gifts to grieving family members is an important way to express care and concern. During the COVID-19 pandemic, consider expressing care in ways that do not involve personal interactions. Consider delivering food or gifts to grieving family members in ways that keep people at least 6 feet apart, mailing care packages, or giving families gift cards for food delivery services.
Avoid touching the deceased person’s body before preparation
There are many different cultural traditions involved in the bereavement process, including some that involve touching the deceased person’s body before preparation. Though we are still learning more about how COVID-19 spreads, it may be possible that you could get COVID-19 by touching the body of a deceased person who had confirmed or suspected COVID-19 prior to the body being prepared for viewing. After the body has been prepared for viewing, there may be less of a chance of the virus spreading from certain types of touching, such as holding the hand or hugging.
Take steps to protect yourself, such as:
- Avoid touching, hugging, or kissing the body of a deceased person who had confirmed or suspected COVID-19 before and during body preparation, especially if you or a member of your household are at higher risk of severe illness from COVID-19.
- Wash your hands with soap and water for at least 20 seconds after any contact with the body. If soap and water are not readily available, use a hand sanitizer that contains at least 60% alcohol.
- Take precautions with rituals that involve touching the deceased person’s body
If the deceased person had confirmed or suspected COVID-19, avoid kissing, washing, or shrouding the body before, during, and after the body has been prepared, if possible. Take precautions if participating in these activities is part of important religious or cultural practices.
- Work with your cultural and religious leaders and funeral home staff to identify how to reduce exposure as much as possible.
- People at higher risk of severe illness from COVID-19 and members of their household should not be involved in these activities.
- People conducting these activities should wear disposable gloves (nitrile, latex, or rubber). Additional protective equipment may also be required, such as disposable and waterproof isolation gowns, face shields or goggles, and facemasks (e.g., if splashing of fluids is expected).
- Following preparation of the body, safely remove gloves (and other protective equipment, if used) and throw them away. Immediately wash your hands with soap and water for at least 20 seconds. If soap and water are not available, use a hand sanitizer that contains at least 60% alcohol. Shower as soon as possible.
- If you did not wear an isolation gown while preparing the body, wash your clothes in the warmest setting possible and dry them completely.
- If removing personal possessions (such as wedding rings) from the body or casket, clean and disinfectexternal icon the items and wash hands right away.
Safely gather your loved one’s belongings
If desired, you may retrieve the belongings of a loved one who has died of COVID-19 outside their home (for example, in a hospital setting). Depending on local rules and regulations, family members may retrieve these belongings at the funeral home or the healthcare facility.
You should use gloves and practice good hand hygiene when handling your loved ones’ belongings. Depending on the type of belongings, such as electronics, you should also follow the household item-specific cleaning and disinfection guidelines when handling these items.
March 2020 Research
Contents
I. Characteristics of Covid-19
A. Epidemiology —
CoVid-19 came from bats in China since December 2019. Apparently, there is a laboratory in Wuhan, China who were studying Corona virus in bats.
B. Other Names
Also known as corona virus, SARS- CoV-2 or Severe Acute Respiratory Syndrome Corona Virus 2, 2019nCoV, Acute Respiratory Disease, Novel corona virus pneumonia, Wuhan Pneumonia
C. Incubation Period & Quarantine Recommendations
2–14 days after exposure and the recommended quarantine is 14 days.
D. Intermediate Hosts
Bats
E. Transmission
Infected person coughing, sneezing, touching other people & objects, feces & blood
F. Prevention of Spread
Wash your hands thoroughly with soap and water for at least 20 sec
Use hand sanitizer with at least 60 percent alcohol if soap isn’t available.
Avoid touching your face unless you’ve recently washed your hands.
Stay clear of people who are coughing and sneezing. The CDC recommends standing at least 6 feet away from anyone who appears to be sick. Cough or sneeze to your clothes.
Disinfect with ultraviolet light (sun) & heat ~ clothes drying
Avoid crowded areas as much as possible
Novel Preventative for CoVid-19. (Not guaranteed). Use Alcohol based Antiseptic mouthwash with eucalyptus, menthol, methyl salicylate & thymol twice a day for 1 minute. Best in incubation stages. May decrease transmission by infected people.
Corona virus has been found to remain infectious on inanimate surfaces at room temperature for 9 days. When the temperature is lower, at 30 degree Celsius, the duration is shorter. The utilization of ethanol between 62–71% killed viruses within 1 minute exposure time. Other effective products are: Concentrations of 0.1–0.5 % sodium hypochlorite and glutardialdehyde 0.1% of bleach (dilution of 1:100 of sodium hypochlorite resulting in 0.05% final concentration is effective in 1 minute. 75% 2-propanol have been effective against SARS-CoV and MERS-CoV are effective
G. Clinical Signs
First signs are loss of taste and smell. Dry cough, tiredness, fever, sore throat, and shortness of breath.
H. Use of face masks
Sick people should be able to breathe fresh air. The use of masks, covering the nose and mouth and re-inhaling the germs & lack of oxygen for prolonged period makes the virus more virulent, developing worse clinical signs leading to death. Due to oxygen deprivation, a person wearing a mask needs to inhale more and germs are sucked into the deeper bronchial area, spreading the virus and worsening pathology. Too much oxygen can cause problems too. Physiologically, Carbon Dioxide is needed to stimulate respiration. When there is lack of CO2 in the blood, the respiratory system does not get stimulated. This can cause death.
I Survival
Survivors experience lung scars pathology
J Differential Diagnosis
* Adenovirus
* Rhinovirus (common cold)
* Respiratory Synctial Virus (RSV)
- Parainfluenza
- Influenza
- Human Metapneumovirus. (HMPV)
According to the CDC, two kinds of tests are available for COVID-19: viral tests and antibody tests.
- A viral serological test tells you if you have a current infection, ie nasal swabs.
- An antibody blood test might tell you if you had a past infection.
II. The Coronavirus
A. Classification
A majority of alphacoronaviruses and betacoronaviruses were identified only in bats, and many coronaviruses phylogenetically related to SARSCoV and MERS-CoV were discovered in diverse bat species. Therefore, emerging zoonotic HCoVs such as SARS-CoV and MERS-CoV likely originated in bats through sequential mutation and recombination of bat coronaviruses, underwent further mutations during the spillover to intermediate hosts, and finally acquired the ability to infect human hosts.
B. Morphology & Genomic Structure of HCoV
Coronaviruses are spherical or pleomorphic, with a diameter of 80–120 nm. Under the electron microscope, the virion surface is decorated with club-like projections constituted by the trimeric spike (S) glycoprotein. Shorter projections made up of the dimeric hemagglutinin-esterase (HE) protein are observed in some beta coronaviruses (such as HCoV-OC43 and HCoV-HKU1). Both S and HE are type I transmembrane proteins with a large ectodomain and a short endodomain. The viral envelope is supported by the membrane (M) glycoprotein, the most abundant structural protein that embeds in the envelope via three transmembrane domains. Additionally, a small transmembrane protein known as the envelope (E) protein is also present in a low amount in the envelope . Finally, the nucleocapsid (N) protein binds to the RNA genome in a beads-on-a-string fashion, forming the helically symmetric nucleocapsid.
The coronavirus genome is a positive, no segment single-stranded RNA, with an astoundingly large size ranging from 27 to 32 kilobases. The genomic RNA is 5 -capped and 3 polyadenylated and contains multiple open reading frames (ORFs). The invariant gene order is 5 replicase-S-E-M-N-3,with numerous small ORFs (encoding accessory proteins) scattered among the structural genes. The coronavirus replicase is encoded by two large overlapping ORFs (ORF1a and ORF1b) occupying about two-thirds of the genome and is directly translated from the genomic RNA. The structural and accessory genes, however, are translated from sub genomic RNAs (sgRNAs) generated during genome transcription/replication as described below.
C. Replication
Diagram 1: Stages of Replication
Infection starts with the attachment of HCoVs to the cognate cellular receptor, which induces endocytosis. Membrane fusion typically occurs in the endosomes, releasing the viral nucleocapsid to the cytoplasm. The genomic RNA (gRNA) serves as the template for translation of polyproteins pp1a and pp1ab, which are cleaved to form nonstructural proteins (nsps). nsps induce the rearrangement of cellular membrane to form double-membrane vesicles (DMVs), where the viral replication transcription complexes (RTCs) are anchored. Full-length gRNA is replicated via a negative-sense intermediate, and a nested set of subgenomic RNA (sgRNA) species are synthesized by discontinuous transcription. These sgRNAs encode viral structural and accessory proteins. Particle assembly occurs in the ER-Golgi intermediate complex (ERGIC), and mature virions are released in smooth-walled vesicles via the secretory pathway.
III. Treatment
A. Inhibitors of Host Factors
B.1. APN Inhibitors
B.2. ACE Inhibitors
B.3. N-Linked Glycosylation Inhibition
B.4. ER Chaperone Inhibitors
B.5. GSK Inhibitors
B.6. IFITM
B.7. TMPRSSIID
B.8. Tubulin
B.9. VCP
B.10. Human Monoclonal Antibody (mAb) to S1
B.11. Neuraminidase Inhibitors
B.12. Use of Microrobots to deliver drug to site
IV. NOVEL PREVENTION & EARLY TREATMENT WITH ALCOHOL BASED ANTISEPTIC MOUTHWASH
A. What is Biofilm?
Aggregate of bacteria, viruses, yeasts protozoa held together by a mucus like matrix of carbohydrate that adheres to a surface. Biofilms can form on the surfaces of liquids, solids, and living issues, such as those of animals and plants. Communities form when individual organisms, which may be of the same or different species, adhere to and accumulate on a surface; this process is called adsorption. Following a period of growth and reproduction, the organisms produce an extracellular matrix consisting of carbohydrates called polysaccharides. This matrix serves to hold the bacteria & virus together and to irreversibly bind them to the surface
VII. References 43
CDC
https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/funeral-guidance.html
NEW YORK TIMES https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
1. https://www.researchandmarkets.com/reports/5011670/coronavirus disease-covid-19-epidemiology
2. Nicdao, F. Coronavirus Survivors Could Suffer Long-Term Lung Damage.
April 27, 2020. https://www.medicaldaily.com/coronavirus-covid-19-ventilator-respiratory-lungs-sars-mers-alveoli-novel-452335
3. INFLUENZA VIRUSES
Bottcher-Friebertshauser, E., Klenk, H., Garten, W.Activation of Influenza viruses by proteases from host cells and bacteria in the human airway epithelium Pathogens and Disease, Volume 69, Issue 2, November 2013, Pages 87–100, https://doi.org/10.1111/2049-632X.12053
4. Lim, Y.X., Ng, Y.L., Tam, J.P., Liu, D.X. Human Coronaviruses: A Review of Virus–Host Interactions. Diseases. 2016 Jul doi: 10.3390/diseases4030026.
PMCID: PMC5456285. PMID: 28933406. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5456285/
5. Cascella, M., Rainik, M., Cuomo, A., Di Napoli, R.Features, Evaluation and Treatment Coronavirus (COVID-19). April 6, 202 https://www.ncbi.nlm.nih.gov/books/NBK554776/
6. Fung, S. Xiang, D. Human Coronavirus: Host-Pathogen Interaction. Annual Review of Microbiology June 21, 2019. 73:529–57. April 11, 2020
7. Kampf et al. “Persistence of coronaviruses on inanimate surfaces and their Inactivation with biocidal agents.” Journal of Hospital Infection Volume 104, Issue 3, March 2020, Pages 246–251. https://www.sciencedirect.com/journal/journal-of-hospital-infection/vol/104/issue/3. April 5, 2020.
8. Lin, L et al. “Antiviral Natural Products and Herbal Medicine”.
J Tradit Complement Med. 2014 Jan-Mar; 4(1): 24–35. doi: 10.4103/2225–4110.124335. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032839/
9. Jia, M., Wei, T., Xu,W. “The Analgesic Activity of Bestatin as a Potent APN Inhibitor”. Frontiers of Neuroscience. 2010; 4:50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903224/
10. https://www.biocompare.com/pfu/120065/soids/200676/Inhibitors/APN
11 https://www.medicinenet.com/ace_inhibitors/
12. https://www.selleckchem.com/products/moexipril-hydrochloride.html
13. Esko, J., Bertozzi, C., and Schnaar, R. Chapter 55. “Chemical Tools for Inhibiting Glycolsylation”. Essentials of Glycobiology [Internet]. 3rd edition.
https://www.ncbi.nlm.nih.gov/books/NBK453074/
14. Reddy, RK, Baumeister, P, et al. “Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.”
https://www.ncbi.nlm.nih.gov/pubmed/12665508
15. Finkelman, H. Martinez, A.”GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS”. Frontiers in Molecular Neuroscience. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204427/
16. Bailey, et al. IFITM-Family Proteins: The Cell’s First Line of Antiviral Defense. Annual Review of Virology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295558
17. Wysocka, M et al.”Substrate specificity and inhibitory study of human airway trypsin-like protease”. Bioorg Med Chem. 2010 Aug 1;18(15):5504–9. doi: 10.1016/j.bmc.2010.06.059. Epub 2010 Jun 22.https://www.ncbi.nlm.nih.gov/pubmed/20620066
18. Arora, et al.”NOVEL MICROTUBULE POLYMERIZATION INHIBITOR WITH POTENT ANTI-PROLIFERATIVE AND ANTI-TUMOR ACTIVITY”. Cancer Res. 2009 Mar 1; 69(5): 1910–1915. 2009 Feb 17. doi: 10.1158/0008–5472.CAN-08–0877. PMCID: PMC2742177. NIHMSID: NIHMS90247 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742177/
19. Saadeh, Y., Vyas,D.”Nanorobotic Applications in Medicine: Current Proposals and Designs”. Am J Robot Surg. 2014 Jun; 1(1): 4–11. doi: 10.1166/ajrs.2014.1010 PMCID: PMC4562685. NIHMSID: NIHMS711465
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562685/
20. https://www.scbt.com/browse/vcp-Inhibitors/_/N-1jj7i6a
21. Gautret P, et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949.
22. Cohen, J. “COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports”. https://www.sciencemag.org/news/2020/04/covid-19-vaccine-protects-monkeys-new-coronavirus-chinese-biotech-reports#
23. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8): 2536–2541.
Published online 2004 Feb 6. doi: 10.1073/pnas.0307140101
24. Sui, J. et al. “Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.” Microbiology. Proceedings of National Academy of Sciences. U S A. 2004 Feb 24; 101(8): 2536–2541.Published online 2004 Feb 6. PMCID: PMC356985 PMID: 14983044 doi: 10.1073/pnas.0307140101
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC356985/
25. Listerine Antiseptic on Biofilm YouTube Video https://www.youtube.com/watch?time_continue=105&v=fRIaessVeJk&feature=emb_logo
26. Biofilm. Encyclopedia Brintannica. https://www.britannica.com/science/biofilm
27. Zhang, W., Du, R., Xing-Lou, X, et al Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Journal. Emerging Microbes & Infections. Volume 9, 2020, Issue 1. https://doi.org/10.1080/22221751.2020.1729071
28. Molecular detection of 2019-nCoV in swabs and blood. Samples were from oral swabs (OS), anal swabs (AS) and blood. (see table at https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1729071 )
29. Kumar, S. et al.Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus Disease. 2020 Mar;31(1):13–21. doi: 10.1007/s13337–020–00571–5. Epub 2020 Mar 5.
30. Eichelberger, M.C., Monto, A.S. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection The Journal of Infectious Diseases, Volume 219, Issue Supplement_1, 15 April 8, 2019, Pages S75–S80, https://doi.org/10.1093/infdis/jiz017
31. Schultze, B. Cavanagh, D. Herrier, G.Neuraminidase treatment of avian infectious bronchitis coronavirus reveals a hemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytes. Virology. 1992 Aug;189(2):792–4.
https://www.ncbi.nlm.nih.gov/pubmed/1322604#
32. Varki, Ajit. ALPHA2–6-LINKED SIALIC ACID EXPRESSION. Cell Biology & Biochemistry. Center for Academic Research and Training Anthropogeny (CARTA). https://carta.anthropogeny.org/moca/domains/cell-biology-and-biochemistry
33. McAuley, J., Gilbertson, B., Trifkovic, S., Brown, L., McKimm-Breschkin, J. Influenza Virus Neuraminidase Structure and Functions. 1Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia
2Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, United States. Frontiers of Microbiology Virology, 29 January 2019 | https://doi.org/10.3389/fmicb.2019.00039
https://www.frontiersin.org/articles/10.3389/fmicb.2019.00039/full
34. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines BMC Bioinformatics. Reviewed by Bui,H. et al 2007; 8: 361.Published online 2007 Sep 26. doi: 10.1186/1471–2105–8–361PMCID: PMC2233646 PMID: 17897458
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2233646/
35. Wang, Y, et al. “T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS”. Journal of Virology. 2004 Jun; 78(11): 5612–5618.doi: 10.1128/JVI.78.11.5612–5618.2004 PMCID: PMC415819 PMID: 15140958W
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC415819/
36. Bhattacharya M. “Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics Approach”. Journal of Medicine Virology. 2020 Feb 28. doi: 10.1002/jmv.25736.